Picture of Carl Zeiss Meditec AG logo

AFX — Carl Zeiss Meditec AG News Story

0.000.00%
de flag iconLast trade - 00:00
HealthcareSpeculativeMid CapFalling Star

Top of the Street: Carl Zeiss, Poste Italiane, Logitech, LondonMetric

A round-up of notable broker activity this morning from Europe's
top-ranked* analysts:
    
    ** Deutsche Bank upgrades Poste Italiane  PST.MI  to "buy"
from "hold," expecting Italy's biggest postal operator to
announce an expansion of its parcels service, new dividend
policy at the Capital Market Day on March 20
    
    INITIATIONS AND REINSTATEMENTS
    ** RBC initiates German medical technology firm Carl Zeiss
 AFXG.DE  with "outperform" and sets PT at 150 euros ($164.12).
The broker sees about 20% earnings-per-share growth to 2027 for
the ophthalmic devices maker
    ** The same broker starts contact lens maker Alcon  ALCC.S 
with "sector perform" and a PT of CHF 85. The broker sees profit
in the mid term for Alcon's core markets, but notes that the
Swiss ophthalmology sector leader's earnings growth outlook is
in line with its peers
    ** Berenberg initiates computer peripheral maker Logitech 
 LOGN.S  with "buy" and a PT of CHF 98 as it expects a gradual
return to the group's historical growth rate of 8-10%, driven by
the replacement cycle for purchases made during the pandemic, as
well as growing gaming and video-collaboration markets
    ** J.P.Morgan reinstates its "overweight" rating on real
estate firm Londonmetric Property  LMPL.L  and sets PT at 230P,
as it sees the merger with LXi enhancing the income security of
the company's portfolio by diversifying across a broad range of
resilient sectors

    
(*Analyst rankings from Thomson Reuters StarMine. The scale is
from 1-star to 5-star with 5 being the best. Analysts are ranked
on earnings accuracy as well as relative performance of
recommendations over trailing 12-month & 24-month periods.)



($1 = 0.9140 euros)

 (Reporting by Antonis Triantafyllou and Alessandro Parodi)
 ((antonis.triantafyllou@tr.com , alessandro.parodi@tr.com))

Recent news on Carl Zeiss Meditec AG

See all news